Immune Regulation: resetting expectations

Immune Regulation is a clinical stage biotech company, pioneering new technologies for resetting the immune system, developing novel, first-in-class therapies for inflammatory and immunological diseases. These therapies exhibit a short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce long-term disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.

Immune Regulation is at the leading edge in the field of developing novel immunomodulatory platforms to address unmet clinical needs, initially in the significant allergy, inflammatory respiratory diseases and rheumatoid arthritis (RA) markets as well as broader potential in other disease indications.

Working with innovative researchers and strategic partners to systematically identify, validate and develop therapeutic candidates, Immune Regulation: resetting expectations.

Our History

Originally founded in 2011 as Peptinnovate, we developed the peptide PIN201104 through preclinical studies and into phase I clinical trials for respiratory diseases.

At the beginning of 2018 we acquired Immune Regulation, another clinical-stage biotech which had already successfully completed a phase I/IIa clinical study in rheumatoid arthritis with its lead candidate IRL201805.

Our Future

As Immune Regulation, our aim is to develop novel, safe and effective therapies that reset the immune system, making the lives of patients with inflammatory and immunological diseases better.

Our scientific team are specialists in translating innovative research into clinical candidates.

To discuss collaboration opportunities with Immune Regulation click here to contact us.